NEW YORK and SHANGHAI, June 18,
2019 /PRNewswire/ -- Cellular Biomedicine Group
Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a
biopharmaceutical firm engaged in the drug development of
immunotherapies for cancer and stem cell therapies for degenerative
diseases, today announced that several of its executives will
participate in the upcoming CAR-TCR Summit Asia to be held in
Shanghai, June 19-20, 2019. The Summit hosts key opinion
leaders in CAR-TCR development, manufacturing and commercialization
as they build their strategies to bring safe and effective CAR-T
and TCR therapies to patients globally.
Panel:
|
CEO Leaders Panel:
Strategic Challenges and Future Priorities for the Next Generation
CAR-T
|
|
and TCR Cell Therapy
Development
|
Panelist:
|
Tony (Bizuo) Liu,
Chief Executive Officer
|
Date:
|
Wednesday, June 19,
2019
|
Time:
|
9:15-10:15 am
(CST)
|
|
|
Presentation:
|
Approaches to Address
the Challenges for Drug Commercialization for Cell and Gene
Therapies: Particularly in China
|
Panelist:
|
Tony (Bizuo) Liu,
Chief Executive Officer
|
Date:
|
Wednesday, June 19,
2019
|
Time:
|
2:45-3:15 pm
(CST)
|
|
|
Presentation:
|
CBMG Cell Therapy
Strategies
|
Panelist:
|
Yihong Yao, Chief
Scientific Officer
|
Date:
|
Thursday, June 20,
2019
|
Time:
|
12:25-12:55 pm
(CST)
|
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of cancer and degenerative diseases. It
conducts immuno-oncology and stem cell clinical trials in
China using products from its
integrated GMP laboratory. Its GMP facilities in China, consisting of 12 independent cell
production lines, are designed and managed according to both
China and U.S. GMP
standards.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts and may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include those
regarding our ability to implement our plans, strategies and
objectives for future operations, including regulatory approval of
our IND applications, our plan to configure part of our
Shanghai facility with GE
Healthcare's FlexFactory platform, our ability to execute on our
obligations under the terms of our licensing and collaboration
arrangement with Novartis, our ability to execute on proposed new
products, services or development thereof, results of our clinical
research and development, regulatory infrastructure governing cell
therapy and cellular biopharmaceuticals, our ability to enter into
agreements with any necessary manufacturing, marketing and/or
distribution partners for purposes of commercialization, our
ability to seek intellectual property rights for our product
candidates, competition in the industry in which we operate,
overall market conditions, any statements or assumptions underlying
any of the foregoing and other risks detailed from time to time in
CBMG's reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
For more information, please contact:
Company Contact:
Derrick C.
Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-executives-to-present-at-car-tcr-summit-asia-300870258.html
SOURCE Cellular Biomedicine Group